Record mula sa primary source
Johnson & Johnson entered into a definitive agreement to acquire Ollin Biosciences for $2.2B upfront plus up to $1.125B in milestones, adding the Phase 3 bispecific antibody OLN324 targeting VEGF and Ang-2 for wet AMD and DME. A separate agreement with Blackstone Life Sciences will provide $750M to fund Phase 3 development of OLN324 in exchange for milestones and royalties. The transaction is expected to close before the end of 2026.
Johnson & Johnson upang makuha ang Ollin Biosciences at late-stage bispecific antibody na may best-in-class na potensyal sa ophthalmology Johnson & Johnson upang makuha ang Ollin Biosciences at late-stage bispecific antibody na may best-in-class na potensyal sa ophthalmology Johnson & Johnson upang makuha ang Ollin Biosciences at late-stage bispecific antibody na may best-in-class na potensyal sa ophthalmology Ang pagkuha ay nagdaragdag ng OLN324, isang Phase 3 investigational bispecific antibody para sa retinal vascular diseases, kabilang ang wet AMD at diabetic macular edema Pinabilis ang ambisyon ng Kumpanya na mapanatili, maibalik at mapahusay ang paningin Itinatayo sa matagal nang presensya ng Johnson & Johnson bilang isang innovator sa paningin Johnson & Johnson (NYSE: JNJ) nga